FDA Determines Regulatory Review Period for Seroquel Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Seroquel, a prescription medication, in accordance with federal regulations. This decision was prompted by a patent extension application submitted to the US Department of Commerce, which aims to prolong the patent protection for the human drug product.